ProKidney has acquired inRegen and its subsidiary Twin City Bio.
ProKidney has arranged an initial capital of $75m for financing the acquisition and funding the clinical development of inRegen’s Renal Advanced Cell Therapy (ReACT).
ReACT is an autologous cell therapy conducted to harness the body’s intrinsic capability to repair the damaged kidney tissues and restore them.
Based in the US, InRegen is a biotechnology company engaged in developing advanced cellular therapies (ACT) for treating chronic kidney disease (CKD), while Twin City Bio is a US-based regenerative medicine company focused on producing cell-based therapy products.
ProKidney is a US-based company led by Pablo Legorreta, the founder and CEO of Royalty Pharma.
Quest Products has announced plans to merge with OraHealth Corporation.
The OraCoat® brand of oral care products and Xylimelts® for dry mouth will be added to Quest’s portfolio following the merger.
OraHealth has engaged Cascadia Capital as its advisor for the transaction, while Carney Badley Spellman acted as legal advisor. Quest has engaged Reinhart Boerner Van Deuren as its legal counsel for the transaction.
Based in the US, OraHealth is engaged in the production and manufacturing of natural and non-acidic oral-adhering discs, while Quest Products, also based in the US, is a leading wholesale distributor of consumer packaged goods.
Gencor Pacific has completed an acquisition of InSight Biopharmaceuticals for $2.5m. The acquisition was made through Gencor’s local subsidiary Kinbio.
Based in Hong Kong, Gencor Pacific is a pharmaceutical and food retailer, while InSight Biopharmaceuticals is focused on providing life sciences and analytical solutions.